Credit Suisse analyst Scott Deuschle maintains TransDigm Gr (NYSE:TDG) with a Outperform and raises the price target from $735 to $765.
Needham Maintains Buy on G1 Therapeutics, Lowers Price Target to $18
Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $31 to $18.